코로나 백신 접종을 위한 의료기관 준비사항 = Preparing for COVID-19 Vaccination: Guidelines for Healthcare Personnel

다국어 초록 (Multilingual Abstract)

In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic. Given the urgent need for vaccines against COVID-19, huge financial investments and global scientific collaborations have been made to develop effective and safe vaccines. To date, WHO has included five COVID-19 vaccines, comprising BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), AZD1222 (AstraZeneca), Ad26.COV2.S (Johnson and Johnson’s Janssen), and BBIBP-CorV (Sinopharm) under WHO Emergency Use Listing as they are considered to meet the necessary criteria for safety and efficacy. In Korea, the Pfizer-BioNTech vaccine and AstraZeneca vaccine have been administered since February 2021, and three more COVID-19 vaccines are scheduled for incorporation till the end of 2021. This article focuses on the clinical and technical considerations of COVID-19 vaccinations to provide accurate and safe guidance for healthcare practitioners. A brief review of COVID-19 vaccines to be introduced in Korea is also summarized.

참고문헌 (Reference)

1 WHO, "WHO coronavirus (COVID-19) dashboard"

2 Pai M, "Vaccine-induced prothrombotic immune thrombocytopenia VIPIT following AstraZeneca COVID-19 vaccination: interim guidance for healthcare professionals in emergency department and inpatient settings" 2021

3 CDC, "Vaccine storage and handling toolkit"

4 Srivatana V, "Vaccine and the need to be heard: considerations for COVID-19 immunization in ESKD" 360 : 2021

5 CDC, "Vaccine administration: intramuscular (IM) injection adults 19 years of age and older"

6 CDC, "Vaccinating dialysis patients and healthcare personnel"

7 Greinacher A, "Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination" 384 : 2092-2101, 2021

8 Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, "The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2" 5 : 536-544, 2020

9 The Transplantation Society, "TID COVID-19 guidance focused review: SARS-CoV-2 vaccines in transplant recipients"

10 European Medicines Agency., "Summary of product characteristics"

11 European Medicines Agency, "Signal assessment report on Embolic and Thrombotic events (SMQ) with COVID-19Vaccine Janssen (Ad26.COV2-S [recombinant])"

12 CDC, "Screen for contraindications and precautions"

13 Monin L, "Safety and immunogenicity of one versus two doses of the COVID-19vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study" 22 : 765-778, 2021

14 Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARSCoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK" 397 : 99-111, 2021

15 Polack FP, "Safety and efficacy of the BNT162b2mRNA Covid-19 vaccine" 383 : 2603-2615, 2020

16 Sadoff J, "Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19" 2021

17 Kim L, "Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)" 72 : e206-e214, 2021

18 Shimabukuro TT, "Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021" 325 : 1101-1102, 2021

19 Medicines and Healthcare products Regulatory Agency, "Regulatory approval of COVID-19 Vaccine AstraZeneca"

20 The Korean Society of Nephrology, "Recommendation on COVID-19 Vaccination for dialysis patients"

21 CDC, "Prevaccination checklist for COVID-19 vaccines"

22 Korean Society of Medical Oncology, "Preliminary guideline of COVID-19 vaccination in Korean cancer patients"

23 Shimabukuro TT, "Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons" 2021

24 Mulligan MJ, "Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults" 586 : 589-593, 2020

25 Geretti AM, "Outcomes of coronavirus disease 2019(COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): a prospective observational study" 2020

26 Novavax, "Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK Phase 3 Trial"

27 National Comprehensive Cancer Network, "NCCN: cancer and COVID-19 vaccination"

28 Korea Disease Control and Prevention Agency, "Monthly safety report after COVID-19 vaccination"

29 Korea Disease Control and Prevention Agency, "Medical expenses for severely ill patients after COVID-vaccination exempted from compensation due to the lack of causality"

30 Resuscitation Council UK, "Management of anaphylaxis in the vaccination setting"

31 Janssen Scientific Affairs, "Janssen COVID-19 Vaccine - stability - temperature excursion (vials)"

32 "Interim guidance for COVID-19and persons with HIV"

33 CDC, "Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States"

34 Minnesota Department of Health, "Interim COVID-19vaccine provider guide"

35 WHO Regional Office for the Western Pacific, "Immunization safety surveillance: guidelines for immunization programme managers on surveillance of adverse events following immunization" WHO Regional Office for the Western Pacific 23-30, 2015

36 Shaw RH, "Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data" 397 : 2043-2046, 2021

37 CDC, "General best practice guidelines for immunization:best practices guidance of the Advisory Committee on Immunization Practices (ACIP)"

38 Docherty AB, "Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study" 369 : m1985-, 2020

39 U.S. Food and Drug Administration, "Fact sheet for healthcare providers administering vaccine. Emergency Use Authorization (EUA) of the Pfizer-BioNTeCH COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19)" Emergency Use Authorization

40 U.S. Food and Drug Administration, "Fact sheet for healthcare providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to prevent coronavirus disease 2019(COVID-19)"

41 U.S. Food and Drug Administration, "Fact sheet for healthcare providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Janssen COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19)"

42 Parry H, "Extended interval BNT162b2 vaccination enhances peak antibody generation in older people" 2021

43 Resuscitation Council UK, "Emergency treatment of anaphylaxis: guidelines for healthcare providers"

44 Shinde V, "Efficacy of NVX-CoV2373 Covid-19vaccine against the B.1.351 variant" 384 : 1899-1909, 2021

45 Baden LR, "Efficacy and safety of the mRNA-1273SARS-CoV-2 vaccine" 384 : 403-416, 2021

46 Medicines and Healthcare products Regulatory Agency, "Coronavirus vaccine - weekly summary of Yellow Card reporting"

47 Stokes EK, "Coronavirus disease 2019 case surveillance - United States, January 22-May 30, 2020" 69 : 759-765, 2020

48 Public Health England, "COVID-19: the green book, chapter 14a"

49 Chirico F, "COVID-19: protecting healthcare workers is a priority" 41 : 1117-, 2020

50 CDC, "COVID-19 vaccine training: general overview of immunization best practices for healthcare providers"

51 WHO, "COVID-19 vaccine tracker"

52 European Medicines Agency, "COVID-19 vaccine safety update: Vaxzevria AstraZeneca AB"

53 Public Health England, "COVID-19 vaccination programme: information for healthcare practitioners"

54 Tesoriero JM, "COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State" 4 : e2037069-, 2021

55 Fung M, "COVID-19 in immunocompromised hosts: what we know so far" 72 : 340-350, 2021

56 Park Jin Kyun, "COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology" 대한의학회 36 (36): 1-12, 2021

57 European Medicines Agency, "AstraZeneca’s COVID-19vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets"

58 Mahase E., "AstraZeneca vaccine: blood clots are “extremely rare” and benefits outweigh risks, regulators conclude" 373 : n931-, 2021

59 Amiral J, "Anticoagulation drugs - the current state of the art" IntechOpen 27-34, 2019

60 Shimabukuro T, "Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine" 325 : 780-781, 2021

61 CDC COVID-19 Response Team, "Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021" 70 : 125-129, 2021